PLoS ONE (Jan 2019)

Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.

  • Tara C Bouton,
  • Margaretha de Vos,
  • Elizabeth J Ragan,
  • Laura F White,
  • Leonie Van Zyl,
  • Danie Theron,
  • C Robert Horsburgh,
  • Robin M Warren,
  • Karen R Jacobson

DOI
https://doi.org/10.1371/journal.pone.0223308
Journal volume & issue
Vol. 14, no. 10
p. e0223308

Abstract

Read online

South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.